Regulatory & Legal

Smart Powerr Corp.'s second reverse split in a year aims to save its Nasdaq listing. This move reveals deep financial strain and a critical test for its pivot to energy storage.

New Dawn Franchising emerges from stealth with a tech-enabled platform aimed at solving the E-2 visa's biggest challenge: finding a stable, compliant U.S. business.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

A new alliance between Keytos Security and Carahsoft provides a critical pathway for government agencies to meet urgent Zero Trust mandates. Here's how.

After a rare rebuke from a top proxy firm forced its hand, kefir maker Lifeway Foods has scrapped its poison pill. But is this a new era or a red flag?

As hurricane season begins, the focus is shifting from stocking supplies to fortifying your home’s critical infrastructure for a faster, safer recovery.

Helsinki leverages its iconic Aalto architecture to redefine urban living, blending heritage with modern business strategy through exhibitions and a UNESCO bid.

When a stock is halted, the real story isn't the frozen price. It's the frantic activity that came before and the systemic risks it reveals for global investors.

A major stock conversion aims to save Alpha Modus from Nasdaq delisting. Is it a savvy financial maneuver or a last-ditch effort for its AI ambitions?

BioCardia secures a crucial $4.4M, extending its runway for a key Japan submission. But a closer look reveals a high-stakes bet on future warrant exercises.

A new R&D pact between ARCYN Defense and the U.S. Army isn't just a press release; it's a strategic maneuver in the multi-billion dollar C-UAS market.

Beta Bionics faces a shareholder investigation after a slowdown in patient growth spooked investors. We decode the numbers and the broader risks of growth metrics.

Medtronic veteran Jesse Litwak joins ProVerum, a move signaling the BPH innovator is shifting from R&D to aggressive commercial scale-up with its new ProVee tech.

A landmark study validates Ceribell's AI in predicting neurological outcomes, signaling a major shift in critical care and bolstering its competitive edge.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

Nyrstar NV is under criminal investigation for forgery and misuse of assets, a blow that threatens to unravel investor confidence and corporate integrity.

A recall of Target's popular baby wipes over dangerous bacteria raises critical questions about private label safety, supplier oversight, and consumer trust.

Horizon Growth's new CEO isn't just a management change; it's the final piece in a year-long transformation from a niche carbon firm to a diversified investor.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?